The HINT1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with HINT1 gene disruption in the NCI-H1975 human lung adenocarcinoma cell line. This heterogeneous pool of edited cells enables loss-of-function studies without clonal bias, serving as a flexible tool for investigating tumor suppressor biology and oncogenic signaling.
The parental NCI-H1975 line, derived from a female non-smoker with lung adenocarcinoma, harbors EGFR L858R and T790M mutations, making it a key model for non-small cell lung cancer and acquired resistance to EGFR inhibitors. It is widely used to study drug resistance mechanisms, including bypass signaling and apoptosis evasion. HINT1 knockout in this background allows dissection of EGFR-driven networks and tumor-suppressive axes.
HINT1 is a tumor suppressor that promotes apoptosis and inhibits Wnt/??-catenin signaling. Transcriptionally activated by p53 upon DNA damage, HINT1 directly binds ??-catenin, preventing its nuclear translocation and repressing TCF/LEF-driven expression of MYC and CCND1. HINT1 also interacts with MITF and USF2 to modulate transcription. Its function integrates p53-mediated apoptotic signals (via BAX and BCL2) with canonical Wnt pathway components (WNT ligands, FZD receptors, DVL, GSK3??, AXIN, APC), placing HINT1 at a critical node controlling cell fate.
In EGFR-mutant NCI-H1975 cells, HINT1 knockout relieves Wnt/??-catenin inhibition, promoting ??-catenin nuclear accumulation and upregulating MYC and CCND1 to enhance proliferation and survival. This model is valuable for studying how HINT1 loss cooperates with oncogenic EGFR to influence sensitivity to osimertinib and for identifying synthetic lethal interactions that could inform combination therapy strategies.
Applications include western blotting for HINT1, ??-catenin, and cleaved caspase-3; RT-qPCR for MYC, CCND1, and AXIN2; and co-immunoprecipitation to assess ??-catenin-HINT1 complexes. Functional assays such as ??-catenin immunofluorescence, Annexin V/PI flow cytometry, MTS viability, and osimertinib dose-response can be performed. Transcriptome profiling via RNA-seq reveals global gene expression changes. This polyclonal knockout population supports research into tumor suppressor networks and drug resistance. For further information, please contact Ascent Research.
